Skybiotech Healt

Why is Skybiotech Healthcare Limited falling/rising?

As of 15-Jul, Skybiotech Healthcare Limited's stock price is Rs 144.00, down 4.0%, with significant underperformance against the Sensex and concerning financial health, including operating losses and a negative EBITDA. The stock has declined 33.94% over the past year, reflecting weak fundamentals and negative investor sentiment.

As of 15-Jul, Skybiotech Healthcare Limited's stock price is falling, currently at Rs 144.00, which reflects a decrease of Rs 6.00 or 4.0%. The stock has been underperforming significantly compared to the benchmark Sensex, with a decline of 15.29% over the past week and 27.24% over the past month. Year-to-date, the stock has dropped by 17.76%, and over the past year, it has fallen by 33.94%, while the Sensex has only decreased by 6.52%.<BR><BR>Today's performance indicates that the stock has underperformed its sector by 4.05%, and it has been on a consecutive decline for the last three days, accumulating a total drop of 10.84% during this period. The stock reached an intraday low of Rs 144, which is 4% lower than its previous close. Additionally, the trading volume has shown erratic patterns, with a significant drop in delivery volume by 72.22% compared to the 5-day average, indicating a lack of investor interest.<BR><BR>The company's financial health is concerning, as it has reported operating losses and a negative EBITDA of Rs -1.46 crore. Over the past five years, net sales have stagnated with an annual growth rate of 0%, and the operating profit has decreased by 1.02%. The high Debt to EBITDA ratio further highlights the company's weak ability to service its debt. Given these factors, including poor long-term growth prospects and significant underperformance relative to the market, the stock's decline is supported by its weak fundamentals and negative investor sentiment.

Which are the latest news on Skybiotech Healt?

What does Skybiotech Healt do?

Skybiotech Healthcare Limited is a micro-cap company in the textiles sector, focusing on spinning, weaving, and finishing garments. It reported net sales of 2 Cr and a net profit of 0 Cr for the quarter ending March 2026.

Overview: <BR>Skybiotech Healthcare Limited is involved in the spinning, weaving, and finishing of textiles within the garments and apparels industry, categorized as a micro-cap company.<BR><BR>History: <BR>The company was initially incorporated as Kapil Cotex Limited in 1983 and changed its name to Skybiotech Healthcare Limited in 2025 with the approval of the Registrar of Companies. The latest reported quarter for sales and profit is March 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 2 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 36 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 32 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 1.13 <BR>Return on Equity: -13.88% <BR>Price to Book: 4.45<BR><BR>Contact Details: <BR>Address: UG-276 Dreams The Mall, Gate No 3 LBS Marg Bhandup (W) Mumbai Maharashtra : 400078 <BR>Tel: 91-022-21660432 <BR>Email: kapilcotexlimited@yahoo.co.in <BR>Website: http://www.kapilcotexlimited

How big is Skybiotech Healt?

As of 10th June, Skybiotech Healthcare Limited has a market capitalization of 36.00 Cr and reported Net Sales of 7.10 Cr with a Net Profit loss of 1.11 Cr over the latest four quarters. The balance sheet for March 2025 shows Shareholder's Funds of 8.99 Cr and Total Assets of 19.18 Cr.

As of 10th June, Skybiotech Healthcare Limited has a market capitalization of 36.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 7.10 Cr. However, it experienced a loss of 1.11 Cr in Net Profit during the same period.<BR><BR>The latest annual period for the balance sheet is March 2025, showing Shareholder's Funds of 8.99 Cr and Total Assets of 19.18 Cr.

Who are in the management team of Skybiotech Healt?

The management team of Skybiotech Healt includes Prakashchandra Rathi (Chairman & CFO), Poonam Rathi (Managing Director), Yogesh Nandlal Chandak (Non Executive Director), Jagdish Manohar Mantri (Independent Director), Rakesh Somani (Independent Director), and Swati Maheshwari (Company Secretary & Compliance Officer).

The management team of Skybiotech Healt includes the following individuals:<BR><BR>1. Prakashchandra Rathi - Chairman & CFO<BR>2. Poonam Rathi - Managing Director<BR>3. Yogesh Nandlal Chandak - Non Executive Director<BR>4. Jagdish Manohar Mantri - Independent Director<BR>5. Rakesh Somani - Independent Director<BR>6. Swati Maheshwari - Company Secretary & Compliance Officer<BR><BR>If you need more information about their roles or the company's activities, feel free to ask!

Who are the peers of the Skybiotech Healt?

Skybiotech Healt's peers include Subhash Silk, Arex Industries, Gem Spinners, and others. It has below average management and growth ratings, with a 1-year return of 16.05%, higher than Arex Industries but lower than Gem Spinners' 61.58%.

Peers: The peers of Skybiotech Healt are Subhash Silk, Arex Industries, Gem Spinners, Anirit Ventures, Akshar Spintex, Tusaldah, Swasti Vinayaka, Suryaamba Spinni, and Vera Synthetic.<BR><BR>Quality Snapshot: Excellent management risk is observed at Suryaamba Spinni and Vera Synthetic, while Average management risk is found at Arex Industries and Swasti Vinayaka. Below Average management risk is noted at Skybiotech Healt, Akshar Spintex, Tusaldah, and the rest. Growth ratings show that Good growth is not present, while Below Average growth is seen at Skybiotech Healt, Akshar Spintex, Tusaldah, and the rest. Capital Structure ratings indicate that Good capital structure is found at Swasti Vinayaka and Vera Synthetic, while Below Average capital structure is observed at Skybiotech Healt, Akshar Spintex, Tusaldah, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Gem Spinners at 61.58%, while the lowest is Arex Industries at -30.58%. Skybiotech Healt's own 1-year return is 16.05%, which is higher than Arex Industries but lower than Gem Spinners. Additionally, the peers with negative six-month returns include Arex Industries, Akshar Spintex, and Swasti Vinayaka.

Should I buy, sell or hold Skybiotech Healthcare Limited?

Are Skybiotech Healthcare Limited latest results good or bad?

Skybiotech Healthcare Limited's latest results show mixed signals; while revenue increased significantly by 90.63% quarter-on-quarter, the company still reported a net loss and negative operating margins, indicating ongoing operational challenges and poor profitability. Investors should be cautious due to the negative return on equity and persistent losses.

Skybiotech Healthcare Limited's latest results present a mixed picture, leaning towards the negative. In Q4 FY26, the company reported a net loss of ₹0.30 crores, which is a 37.50% decrease in losses compared to the previous quarter. While this indicates some improvement, the operating margin remains deeply negative at -48.09%, reflecting ongoing operational challenges.<BR><BR>On a more positive note, revenue surged by 90.63% quarter-on-quarter to ₹1.83 crores, showing a significant recovery from the previous quarter's decline. Year-on-year, revenue also increased by 79.41%. However, this revenue growth has not translated into profitability, as the company continues to struggle with converting sales into operating profits.<BR><BR>The return on equity (ROE) is notably negative at -26.36%, indicating poor capital efficiency and value destruction for shareholders. Additionally, the company has faced persistent operational losses over several quarters, raising concerns about its long-term viability.<BR><BR>Overall, while there are signs of revenue recovery, the underlying operational issues and negative profitability metrics suggest that the results are more indicative of ongoing struggles rather than a solid turnaround. Investors should approach with caution, given the company's weak fundamentals and the lack of institutional interest.

When is the next results date for Skybiotech Healthcare Limited?

The next results date for Skybiotech Healthcare Limited is 30 May 2026.

The next results date for Skybiotech Healthcare Limited is scheduled for 30 May 2026.

How has been the historical performance of Kapil Cotex?

Kapil Cotex experienced significant financial challenges in the fiscal year ending March 2025, reporting net sales of 7.05 Cr but incurring substantial losses with a profit after tax of -2.37 Cr and a net cash outflow of 9.00 Cr, resulting in a closing cash equivalent of 0.00 Cr. Despite increased sales, the company faced rising costs and a decline in profitability compared to the previous year.

Answer:<BR>The historical performance of Kapil Cotex shows significant changes from March 2024 to March 2025.<BR><BR>Breakdown:<BR>In the fiscal year ending March 2025, Kapil Cotex reported net sales of 7.05 Cr, a notable increase from 0.00 Cr in the previous year. However, the total operating income also remained at 7.05 Cr, with raw material costs amounting to 3.67 Cr and total expenditure excluding depreciation rising sharply to 9.31 Cr from just 0.13 Cr. This led to an operating profit (PBDIT) of -1.88 Cr, a decline from a positive 1.87 Cr in March 2024. The company faced a profit before tax of -2.43 Cr, down from 1.88 Cr, resulting in a profit after tax of -2.37 Cr compared to 1.54 Cr the previous year. The earnings per share (EPS) reflected this downturn, falling to -12.34 from 8.02. On the balance sheet, total liabilities stood at 19.18 Cr, with total assets also at 19.18 Cr, indicating a balanced position but with significant debt of 7.20 Cr. The cash flow analysis revealed a net cash outflow of 9.00 Cr, leading to a closing cash equivalent of 0.00 Cr. Overall, the financial results indicate a challenging year for Kapil Cotex, marked by increased sales but substantial losses and cash flow issues.

Who are the top shareholders of the Kapil Cotex?

The top shareholder of Kapil Cotex is Prakashchandra Rathi, holding 45.16%, with no pledged promoter holdings. The highest public shareholder is Ganesh Shivprasad Lahoti at 4.44%, while individual investors own 33.96% of the shares.

The top shareholders of Kapil Cotex include the promoters, with Prakashchandra Rathi holding the largest share at 45.16%. There are no pledged promoter holdings, and the company does not have any mutual fund or foreign institutional investor (FII) holdings. The highest public shareholder is Ganesh Shivprasad Lahoti, who holds 4.44%. Additionally, individual investors collectively hold 33.96% of the shares.

Is Kapil Cotex overvalued or undervalued?

As of April 25, 2023, Kapil Cotex is considered a risky investment due to its negative financial ratios and poor stock performance, indicating it is overvalued compared to peers in the garments and apparel industry.

As of 25 April 2023, the valuation grade for Kapil Cotex has moved from does not qualify to risky, indicating a significant shift in its perceived investment quality. The company appears to be overvalued based on its financial ratios, which include a PE ratio of -11.70, an EV to EBITDA of -15.57, and a Price to Book Value of 3.08. These negative ratios suggest that the company is struggling to generate profits and is not performing well relative to its asset base.<BR><BR>In comparison with peers, Kapil Cotex's valuation metrics are starkly unfavorable. For instance, Altius Telecom, categorized as very attractive, has a PE ratio of 52.97, while Embassy Office REIT is considered very expensive with a PE ratio of 23.06. The stark contrast in these ratios highlights the challenges faced by Kapil Cotex in the garments and apparel industry. Additionally, the company's recent stock performance has been poor, with a year-to-date return of -47.63% compared to a positive 5.56% return for the Sensex, reinforcing the notion that Kapil Cotex is currently overvalued.

What is the technical trend for Kapil Cotex?

As of May 29, 2025, Kapil Cotex's technical trend has shifted to a moderate bearish stance, driven by bearish signals from the MACD, Bollinger Bands, and moving averages, despite a mildly bullish KST.

As of 29 May 2025, the technical trend for Kapil Cotex has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. Key indicators driving this include the weekly MACD and Bollinger Bands both indicating bearish conditions, along with daily moving averages also showing a bearish trend. The KST on a weekly basis is mildly bullish, but this is overshadowed by the overall bearish signals from other indicators. The Dow Theory reflects a mildly bearish stance on both weekly and monthly time frames, further supporting the bearish outlook.

Has Kapil Cotex declared dividend?

No Dividend History Available